Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 161Neoplasm Metastasis 22Neoplasms 20Advanced Breast Cancer 13Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Hereditary Sensory and Autonomic Neuropathies 9Endometrial Neoplasms 8Triple Negative Breast Neoplasms 7Colorectal Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Recurrence 4Neoplasms by Site 4Multiple Endocrine Neoplasia Type 1 4Breast Diseases 4Small Cell Lung Carcinoma 3Head and Neck Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Neoplasms 2Stomach Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Liposarcoma 2HER2-positive Metastatic Breast Cancer 2Advanced Solid Tumors 2Advanced Solid Tumor 2Urologic Neoplasms 1

Interventions

Pemetrexed 13Cisplatin 12Nivolumab 5Carboplatin 5pembrolizumab 4Ipilimumab 4Cyclophosphamide 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3fludarabine 3defactinib 3amatuximab 2Paclitaxel 2Gemcitabine 2Drug Therapy 2tremelimumab 1tazemetostat 1osimertinib 1napabucasin 1enzalutamide 1bemcentinib 1abemaciclib 1VS-5584 1Trabectedin 1Thiostrepton 1Safety 1Panobinostat 1Monatide (IMS 3015) 1Midazolam 1Letrozole 1LY3023414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Mesothelioma, Malignant × Fulvestrant × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡